Fennec Pharmaceuticals Inc. has repurchased and redeemed all outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP, totaling $21,729,455.30. The Company has no outstanding debt after this redemption. Fennec Pharmaceuticals is focused on fighting ototoxicity in cancer patients receiving cisplatin-based chemotherapy, with its product PEDMARK® approved in the U.S., Europe, and the U.K. PEDMARK® has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI® has received Pediatric Use Marketing Authorization in Europe. Fennec has patents protecting PEDMARK® until 2039.

Read more at GlobeNewswire: Fennec Pharmaceuticals Announces Completion Of Full Debt